Form 4: Xeris Biopharma Holdings Director John P. Schmid Acquires Additional Shares
SEC Form 4 Filing
Director John P. Schmid of Xeris Biopharma Holdings, Inc. reports purchasing 4,500 shares of common stock at $2.16 per share.
Summary
- On March 14, 2024, John P. Schmid, a director of Xeris Biopharma Holdings, Inc., acquired 4,500 shares of common stock at a price of $2.16 per share.
- Following the transaction, Schmid directly owns 63,159 shares of Xeris Biopharma Holdings, Inc.
- Schmid also indirectly owns 11,000 shares through The Schmid Family Trust dated August 15, 2017, but disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the scale of the purchase is not significant enough to drastically alter sentiment.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by regulators and investors as it can provide insights into a company's performance and future prospects. Form 4 filings are a routine part of this monitoring process.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| August 15, 2017 | Date of The Schmid Family Trust |
| 03/14/2024 | Date of transaction: John P. Schmid acquired 4,500 shares of common stock |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.